Anne Vinkel Hansen

Anne Vinkel Hansen

Auto-generated profile, based on publicly available information

Anne Vinkel Hansen

Section of Social Medicine, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2010 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JKJeanette Kaae
Jeanette Kaae
AHAnne V. Hansen
Anne V. Hansen
RBRobert J. Biggar
Robert J. Biggar
HBHeather Boyd
Heather Boyd
Patrick S. MoorePatrick S. Moore
Patrick S. Moore
MMMads Melbye
Mads Melbye
Merkel cell carcinoma (MCC) is a rare skin cancer that was recently found to be associated with a polyomavirus and with immunosuppression, provoking new interest in its epidemiology. We conducted a nationwide study in Denmark to describe MCC incidence and mortality and the association between MCC and other cancers. We used data from Danish national health and population registers on MCC diagnoses, deaths, and population counts during the study period (1978–2006) to calculate MCC incidence rates, cumulative risks of MCC at age 100 years, and MCC mortality rates by tumor stage. We used Poisson regression to estimate the excess mortality rate ratio attributable to MCC and examined associations between MCC and other cancers diagnosed before and after the MCC diagnosis using standardized incidence rate ratios (SIRs). All statistical tests were two-sided. Between January 1, 1978, and December 31, 2006, 185 persons were diagnosed with MCC in Denmark. MCC incidence between 1995 and 2006 was 2.2 cases per million person-years. In the first year after MCC diagnosis, 22% of persons with localized disease died compared with 54% of patients with nonlocalized disease; by 5 years after diagnosis, the proportions of MCC patients who had died increased to 55% and 84%, respectively. MCC incidence was statistically significantly increased more than 1 year after a diagnosis of squamous cell carcinoma of the skin (SIR = 14.6, 95% confidence interval [CI] = 8.4 to 25.6), basal cell carcinoma (SIR = 4.3, 95% CI = 2.7 to 6.6), malignant melanoma (SIR = 3.3, 95% CI = 1.1 to 10.3), chronic lymphocytic leukemia (SIR = 12.0, 95% CI = 3.8 to 37.8), Hodgkin lymphoma (SIR = 17.6, 95% CI = 2.5 to 126), and non-Hodgkin lymphoma (SIR = 5.6, 95% CI = 1.4 to 22.4). Squamous cell carcinoma (SIR = 12.1, 95% CI = 5.1 to 29.1) and chronic lymphocytic leukemia (SIR = 14.7, 95% CI = 3.7 to 58.8) occurred in statistically significant excess more than 1 year after MCC diagnosis. These results support the existence of shared risk factors for MCC and other cancers. Heightened awareness of the association between MCC and other cancers, particularly squamous cell carcinoma and chronic lymphocytic leukemia, may facilitate earlier clinical detection and treatment of MCC, thereby improving patient survival.

28 October 2014 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
RCRa Charlton
Ra Charlton
Sue JordanSue Jordan
Sue Jordan
APAnna Pierini
Anna Pierini
EGE Garne
E Garne
ANAj Neville
Aj Neville
LBLtw de Jong‐Van Den Berg
Ltw de Jong‐Van Den Berg
Objective: To explore the prescribing patterns of selective serotonin reuptake inhibitors (SSRIs) before, during and after pregnancy in six European population‐based databases.Design: Descriptive drug utilisation study.Setting: Six electronic healthcare databases in Denmark, the Netherlands, Italy (Emilia Romagna/Tuscany), Wales and the rest of the UK.Population: All women with a pregnancy ending in a live or stillbirth starting and ending between 2004 and 2010.Methods: A common protocol was implemented across databases to identify SSRI prescriptions issued (UK) or dispensed (non‐UK) in the year before, during or in the year following pregnancy.Main outcome measures: The percentage of deliveries in which the woman received an SSRI prescription in the year before, during or in the year following pregnancy. We also compared the choice of SSRIs and changes in prescribing over the study period.Results: In total, 721 632 women and 862 943 deliveries were identified. In the year preceding pregnancy, the prevalence of SSRI prescribing was highest in Wales [9.6%; 95% confidence interval (CI95), 9.4–9.8%] and lowest in Emilia Romagna (3.3%; CI95, 3.2–3.4%). During pregnancy, SSRI prescribing had dropped to between 1.2% (CI95, 1.1–1.3%) in Emilia Romagna and 4.5% (CI95, 4.3–4.6%) in Wales. The higher UK pre‐pregnancy prescribing rates resulted in higher first trimester exposures. After pregnancy, SSRI prescribing increased most rapidly in the UK. Paroxetine was more commonly prescribed in the Netherlands and Italian regions than in Denmark and the UK.Conclusions: The higher SSRI prescribing rates in the UK, compared with other European regions, raise questions about differences in the prevalence and severity of depression and its management in pregnancy across Europe.

24 March 2014 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
RCRachel A. Charlton
Rachel A. Charlton
ANAmanda J. Neville
Amanda J. Neville
Sue JordanSue Jordan
Sue Jordan
APAnna Pierini
Anna Pierini
CDChristine Damase‐Michel
Christine Damase‐Michel
CVCorinne S. de Vries
Corinne S. de Vries
Purpose: The aim of this study was to describe a number of electronic healthcare databases in Europe in terms of the population covered, the source of the data captured and the availability of data on key variables required for evaluating medicine use and medicine safety during pregnancy.Methods: A sample of electronic healthcare databases that captured pregnancies and prescription data was selected on the basis of contacts within the EUROCAT network. For each participating database, a database inventory was completed.Results: Eight databases were included, and the total population covered was 25 million. All databases recorded live births, seven captured stillbirths and five had full data available on spontaneous pregnancy losses and induced terminations. In six databases, data were usually available to determine the date of the woman's last menstrual period, whereas in the remainder, algorithms were needed to establish a best estimate for at least some pregnancies. In seven databases, it was possible to use data recorded in the databases to identify pregnancies where the offspring had a congenital anomaly. Information on confounding variables was more commonly available in databases capturing data recorded by primary‐care practitioners. All databases captured maternal co‐prescribing and a measure of socioeconomic status.Conclusion: This study suggests that within Europe, electronic healthcare databases may be valuable sources of data for evaluating medicine use and safety during pregnancy. The suitability of a particular database, however, will depend on the research question, the type of medicine to be evaluated, the prevalence of its use and any adverse outcomes of interest. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.

1 November 2010 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
JKJeanette Kaae
Jeanette Kaae
HBHeather Boyd
Heather Boyd
AHAnne V. Hansen
Anne V. Hansen
HWHans Christian Wulf
Hans Christian Wulf
JWJan Wohlfahrt
Jan Wohlfahrt
MMMads Melbye
Mads Melbye
Background: Many commonly used medications, including both medications for long-term (daily) use and short-term use (treatment courses of finite duration), have photosensitizing properties. Whether use of these medications affects skin cancer risk, however, is unclear. Methods: Using a cohort of all Danish residents ≥15 years old in 1995 to 2006 (n = 4,761,749) and information from Danish national registers, we examined associations between use of photosensitizing medications and risk of basal cell carcinoma, cutaneous malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma. Results: Users of only 2 of 19 medications for long-term use (methyldopa and furosemide) had both a ≥20% increased risk of skin cancer (compared with nonusers) and an increase in risk with increasing duration of use; these effects were limited to basal cell carcinoma and squamous cell carcinoma, respectively. In contrast, 8 of 10 medications for short-term use were associated with both a ≥20% increased risk of skin cancer and an increase in risk with increasing use for at least one of the four cancers. Conclusion: We found little evidence of an increased risk of skin cancer among users of photosensitizing medications for long-term daily use, but could not rule out the possibility that users of some photosensitizing medications for short-term use may have an increased risk of skin cancer. Impact: Previous studies have been limited to specific medication types (e.g., antidiuretics). Our study examined the effect of a wide range of photosensitizing medications on skin cancer risk and suggests that future work should focus on photosensitizing medications for short-term use. Cancer Epidemiol Biomarkers Prev; 19(11); 2942–9. ©2010 AACR.

1 December 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
EGEster Garne
Ester Garne
AHAnne Vinkel Hansen
Anne Vinkel Hansen
JMJOAN KATHERINE MORRIS
JOAN KATHERINE MORRIS
LZLouise Zaupper
Louise Zaupper
MAMarie-Claude Addor
Marie-Claude Addor
HDHelen Dolk
Helen Dolk
Pregnant women with asthma need to take medication during pregnancy. We sought to identify whether there is an increased risk of specific congenital anomalies after exposure to antiasthma medication in the first trimester of pregnancy. We performed a population-based case-malformed control study testing signals identified in a literature review. Odds ratios (ORs) of exposure to the main groups of asthma medication were calculated for each of the 10 signal anomalies compared with registrations with nonchromosomal, nonsignal anomalies as control registrations. In addition, exploratory analyses were done for each nonsignal anomaly. The data set included 76,249 registrations of congenital anomalies from 13 EUROmediCAT registries. Cleft palate (OR, 1.63; 95% CI, 1.05-2.52) and gastroschisis (OR, 1.89; 95% CI, 1.12-3.20) had significantly increased odds of exposure to first-trimester use of inhaled β2-agonists compared with nonchromosomal control registrations. Odds of exposure to salbutamol were similar. Nonsignificant ORs of exposure to inhaled β2-agonists were found for spina bifida, cleft lip, anal atresia, severe congenital heart defects in general, or tetralogy of Fallot. None of the 4 literature signals of exposure to inhaled steroids were confirmed (cleft palate, cleft lip, anal atresia, and hypospadias). Exploratory analyses found an association between renal dysplasia and exposure to the combination of long-acting β2-agonists and inhaled corticosteroids (OR, 3.95; 95% CI, 1.99-7.85). The study confirmed increased odds of first-trimester exposure to inhaled β2-agonists for cleft palate and gastroschisis and found a potential new signal for renal dysplasia associated with combined long-acting β2-agonists and inhaled corticosteroids. Use of inhaled corticosteroids during the first trimester of pregnancy seems to be safe in relation to the risk for a range of specific major congenital anomalies.

4 March 2014 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
KHKatia Buch Hærvig
Katia Buch Hærvig
LMLaust Hvas Mortensen
Laust Hvas Mortensen
AHAnne Vinkel Hansen
Anne Vinkel Hansen
KSKatrine Strandberg‐Larsen
Katrine Strandberg‐Larsen